A Pilot Dose Ranging Study of Dysport (AbobotulinumtoxinA) in the Treatment of Oromandibular Dystonia

Trial Profile

A Pilot Dose Ranging Study of Dysport (AbobotulinumtoxinA) in the Treatment of Oromandibular Dystonia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Dystonia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 28 Apr 2017 Results assessing the efficacy and safety of botulinum toxin A [Dysport, abobotulinumtoxinA] in patients with oromandibular dystonia, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top